PCLA:NASDAQPicoCELA Inc. Analysis
Data as of 2026-07-08 - not real-time
$4.73
Latest Price
8/10Risk
Risk Level: High
Executive Summary
PicoCELA Inc. is trading at $4.73, which sits below its 20‑day SMA of $5.12 but above the 50‑day SMA of $4.53, indicating mixed short‑term momentum. The 14‑day RSI of 48 suggests the stock is neither overbought nor oversold, while the MACD histogram is negative and the signal line is bearish, pointing to downward pressure. Volume is on an increasing trend, yet the 30‑day volatility of 372% and a beta of 2.19 signal extreme price swings and heightened market sensitivity. The fear‑and‑greed index is at an "Extreme Greed" level of 91.25, reflecting a broadly optimistic market despite the stock’s fragile fundamentals. Fundamentally, the company posted a 42% revenue decline and operates at a loss with operating and profit margins of -106% and -115% respectively. Negative EBITDA of $574.9 M and free cash flow of -$412.7 M underscore cash‑flow challenges. However, the balance sheet shows $534.9 M in cash against $281.6 M of debt, giving a net cash position that could support short‑term operations. The price‑to‑sales ratio of 0.08 and price‑to‑book of 1.88 suggest the market is pricing the stock at a steep discount relative to its assets and sales. With a max drawdown of nearly -99%, the stock has experienced severe price erosion, and the absence of dividends eliminates any income cushion. Overall, the technical indicators are bearish, the fundamentals are weak, and the risk profile is high, making the current valuation appear speculative rather than value‑driven.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 8/10
Key Factors
- Bearish MACD and negative histogram
- Extreme price volatility and high beta
- Continued operating losses and negative cash flow
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Substantial cash reserves offsetting debt
- Potential upside from licensing of mesh technology
- Uncertain revenue recovery amid declining sales
Long Term
> 3 yearsNeutral
Model confidence: 4/10
Key Factors
- Low price-to-sales and price-to-book ratios offer upside if turnaround occurs
- Persistent negative margins limit growth prospects
- High market volatility could erode any long‑term gains
Key Metrics & Analysis
Financial Health
Revenue Growth-42.30%
Profit Margin-114.98%
ROE-151.88%
ROA-32.38%
Debt/Equity59.91
P/B Ratio1.9
Op. Cash Flow$-544019968
Free Cash Flow$-412667616
Industry P/E15.9
Technical Analysis
TrendNeutral
RSI48.0
Support$3.01
Resistance$11.56
MA 20$5.12
MA 50$4.53
MA 200$6.64
MACDBearish
VolumeIncreasing
Fear & Greed Index91.25
Valuation
GradeUndervalued
TypeValue
Risk Assessment
Beta2.19
Volatility372.04%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.